Effects of Pituitary Adenylate Cyclase Activating Polypeptide on Cell Death

Int J Mol Sci. 2022 Apr 29;23(9):4953. doi: 10.3390/ijms23094953.

Abstract

Pituitary adenylate cyclase activating polypeptide (PACAP) was first isolated as a hypothalamic peptide based on its efficacy to increase adenylate cyclase (AC) activity. It has a widespread distribution throughout the body including the nervous system and peripheral organs, where PACAP exerts protective effects both in vivo and in vitro through its anti-apoptotic, anti-inflammatory, and antioxidant functions. The aim of the present paper was to review the currently available literature regarding the effects of PACAP on cell death in vitro in neural and non-neural cells. Among others, its effect on apoptosis can be detected in cerebellar granule cells against different toxic stimuli. Different neural cell types from the cerebral cortex are also prevented from cell death. PACAP also shows effects on cell death in cells belonging to the peripheral nervous system and protects both neural and non-neural cells of sensory organs. In addition, cell survival-promoting effect can be observed in different peripheral organ systems including cardiovascular, immune, respiratory, gastrointestinal, urinary, and reproductive systems. The studies summarized here indicate its noteworthy effect on cell death in different in vitro models, suggesting PACAP's potential therapeutic usage in several pathological conditions.

Keywords: PACAP; apoptosis; cell death; in vitro.

Publication types

  • Review

MeSH terms

  • Apoptosis
  • Cell Death
  • Cell Survival
  • Pituitary Adenylate Cyclase-Activating Polypeptide* / metabolism
  • Pituitary Adenylate Cyclase-Activating Polypeptide* / pharmacology
  • Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I*

Substances

  • Pituitary Adenylate Cyclase-Activating Polypeptide
  • Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I